Folt, D A; Evans, Ka L; Brahmandam, Sravya; He, Wencan; Brewster, Pamela S; Yu, Shipeng; Murphy, Timothy P; Cutlip, Donald E; Dworkin, Lance D; Jamerson, Kenneth; Henrich, William; Kalra, Philip A; Tobe, Sheldon; Thomson, Ken; Holden, Andrew; Rayner, Brian L; Grinfeld, Liliana; Haller, S T; Cooper, Christopher J
For people enrolled in Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), we sought to examine whether variation exists in the baseline medical therapy of different geographic regions and if any variations in prescribing patterns were associated with physician specialty. Patients were grouped by location within the United States (US) and outside the US (OUS), which includes Canada, South America, Europe, South Africa, New Zealand, and Australia. When comparing US to OUS, participants in the US took fewer anti-hypertensive medications (1.9 ± 1.5 vs. 2.4 ± 1.4; P < .001) and were less likely to be treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (46% vs. 62%; P < .001), calcium channel antagonist (37% vs. 58%; P < .001), and statin (64% vs. 75%; P < .05). In CORAL, the identification of variations in baseline medical therapy suggests that substantial opportunities exist to improve the medical management of patients with atherosclerotic renal-artery stenosis.